Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cellular Oncology
Erschienen in: Cellular Oncology 4/2020

11.05.2020 | Report

Zebularine-induced myeloma cell death is accompanied by decreased c-Myc expression

verfasst von: Patryk Krzeminski, Ramón García-Sanz, Norma C. Gutiérrez

Erschienen in: Cellular Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Epigenetic therapies have proven to be clinically effective in several hematological malignancies. Here, we aimed to evaluate the effect of a second-generation DNA demethylation agent, zebularine, on multiple myeloma (MM).

Methods

Western blot, ELISA, qRT-PCR, proliferation assays and cell transfection were used to investigate the mechanism of action of zebularine in MM.

Results

We found that zebularine induced apoptosis and DNA demethylation in most of the MM cell lines tested. Its cytotoxic effect was associated with a time-dependent decrease in the level of c-Myc protein. Moreover, zebularine induced H2AX phosphorylation, a surrogate marker of DNA damage, in five out of eight MM cell lines tested.

Conclusions

Our study revealed novel effects of zebularine on MM that may have potential implications for DNA methylation-based therapies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
S.B. Baylin, M. Esteller, M.R. Rountree, K.E. Bachman, K. Schuebel, J.G. Herman, Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10, 687–692 (2001)CrossRef
2.
B.A. Walker, C.P. Wardell, L. Chiecchio, E.M. Smith, K.D. Boyd, A. Neri, F.E. Davies, F.M. Ross, G.J. Morgan, Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117, 553–562 (2011)CrossRef
3.
E. Braggio, A. Maiolino, M.E. Gouveia, R. Magalhães, J.T. Souto Filho, M. Garnica, M. Nucci, I.Z. Renault, Methylation status of nine tumor suppressor genes in multiple myeloma. Int. J. Hematol. 91, 87–96 (2010)CrossRef
4.
C.M. Bender, M.L. Gonzalgo, F.A. Gonzales, C.T. Nguyen, K.D. Robertson, P.A. Jones, Roles of cell division and gene transcription in the methylation of CpG Islands. Mol. Cell. Biol. 19, 6690–6698 (1999)CrossRef
5.
K. Maes, E. De Smedt, M. Lemaire, H. De Raeve, E. Menu, E. Van Valckenborgh, S. McClue, K. Vanderkerken, E. De Bruyne, The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget 5, 3115–3129 (2014)CrossRef
6.
T. Kiziltepe, T. Hideshima, L. Catley, N. Raje, H. Yasui, N. Shiraishi, Y. Okawa, H. Ikeda, S. Vallet, S. Pozzi, K. Ishitsuka, E.M. Ocio, D. Chauhan, K.C. Anderson, 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol. Cancer Ther. 6, 1718–1727 (2007)CrossRef
7.
J. Laliberté, V.E. Marquez, R.L. Momparler, Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase. Cancer Chemother. Pharmacol. 30, 7–11 (1992)CrossRef
8.
B.A. Chabner, J.C. Drake, D.G. Johns, Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Biochem. Pharmacol. 22, 2763–2765 (1973)CrossRef
9.
C. Stresemann, B. Brueckner, T. Musch, H. Stopper, F. Lyko, Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 66, 2794–2800 (2006)CrossRef
10.
L. Zhou, X. Cheng, B.A. Connolly, M.J. Dickman, P.J. Hurd, D.P. Hornby, Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J. Mol. Biol. 321, 591–599 (2002)CrossRef
11.
J.C. Cheng, C.B. Yoo, D.J. Weisenberger, J. Chuang, C. Wozniak, G. Liang, V.E. Marquez, S. Greer, T.F. Orntoft, T. Thykjaer, P.A. Jones, Preferential response of cancer cells to zebularine. Cancer Cell 6, 151–158 (2004)CrossRef
12.
P. Krzeminski, M.E. Sarasquete, I. Misiewicz-Krzeminska, R. Corral, L.A. Corchete, A.A. Martín, R. García-Sanz, J.F. San Miguel, N.C. Gutiérrez, Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. Biochim. Biophys. Acta 1849, 353–366 (2015)CrossRef
13.
J. Sambrook, E. F. Fritsch, T. Maniatis, Molecular Cloning: A Laboratory Manual. Mol. Cloning Lab. Man. (1989).
14.
M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254 (1976)CrossRef
15.
E.M. Hurt, S.B. Thomas, B. Peng, W.L. Farrar, Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. Cancer Biol Ther 5, 1154–1160 (2006)CrossRef
16.
J.C. Cheng, D.J. Weisenberger, F.A. Gonzales, G. Liang, G.-L. Xu, Y.-G. Hu, V.E. Marquez, P.A. Jones, Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell. Biol. 24, 1270–1278 (2004)CrossRef
17.
M.L. Orta, N. Pastor, E. Burgos-Morón, I. Domínguez, J.M. Calderón-Montaño, C. Huertas Castaño, M. López-Lázaro, T. Helleday, S. Mateos, Zebularine induces replication-dependent double-strand breaks which are preferentially repaired by homologous recombination. DNA Repair 57, 116–124 (2017)CrossRef
18.
C. Grandjenette, M. Schnekenburger, T. Karius, J. Ghelfi, A. Gaigneaux, E. Henry, M. Dicato, M. Diederich, 5-aza-2′-deoxycytidine-mediated c-myc down-regulation triggers telomere-dependent senescence by regulating human telomerase reverse transcriptase in chronic myeloid leukemia. Neoplasia 6, 511–528 (2014)
19.
C.B. Yoo, R. Valente, C. Congiatu, F. Gavazza, A. Angel, M.A. Siddiqui, P.A. Jones, C. McGuigan, V.E. Marquez, Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2′-deoxyzebularine. J. Med. Chem. 51, 7593–7601 (2008)CrossRef
20.
D. Dytfeld, M. Luczak, T. Wrobel, L. Usnarska-Zubkiewicz, K. Brzezniakiewicz, K. Jamroziak, K. Giannopoulos, A. Przybylowicz-Chalecka, B. Ratajczak, J. Czerwinska-Rybak, A. Nowicki, M. Joks, E. Czechowska, M. Zawartko, T. Szczepaniak, N. Grzasko, M. Morawska, M. Bochenek, T. Kubicki, M. Morawska, K. Tusznio, A. Jakubowiak, M. Komarnicki, D. Dytfeld, M. Luczak, T. Wrobel, L. Usnarska-Zubkiewicz, K. Brzezniakiewicz, K. Jamroziak, K. Giannopoulos, A. Przybylowicz-Chalecka, B. Ratajczak, J. Czerwinska-Rybak, A. Nowicki, M. Joks, E. Czechowska, M. Zawartko, T. Szczepaniak, N. Grzasko, M. Morawska, M. Bochenek, T. Kubicki, M. Morawska, K. Tusznio, A. Jakubowiak, M. Komarnicki, Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget 7, 56726–56736 (2016)CrossRef
21.
J.H. Beumer, J.L. Eiseman, R.A. Parise, E. Joseph, J.L. Holleran, J.M. Covey, M.J. Egorin, Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine in mice. Clin. Cancer Res. 12, 7483–7491 (2006)
22.
M. Billam, M.D. Sobolewski, N.E. Davidson, Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res. Treat. 120, 581–592 (2010)CrossRef
23.
M. Lemaire, L.F. Momparler, M.L. Bernstein, V.E. Marquez, R.L. Momparler, Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia. Anti-Cancer Drugs 16, 301–308 (2005)CrossRef
24.
Z. Zhang, Q. He, Y. Tao, J. Guo, F. Xu, L.-Y. Wu, Y.-S. Zhao, D. Wu, L.-Y. Zhou, J.-Y. Su, L.-X. Song, C. Xiao, X. Li, C.-K. Chang, Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes. Am. J. Transl. Res. 9, 454–465 (2017)PubMedPubMedCentral
25.
Y. Cui, A. Naz, D.H. Thompson, J. Irudayaraj, Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide. Mol. Pharm. 12, 1279–1288 (2015)CrossRef
26.
Y. Cao, G.-Q. Qiu, H.-Q. Wu, Z.-L. Wang, Y. Lin, W. Wu, X.-B. Xie, W.-Y. Gu, Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells. Mol. Med. Rep. 14, 3469–3475 (2016)CrossRef
27.
M.B. Heckmann, S. Doroudgar, H.A. Katus, L.H. Lehmann, Cardiovascular adverse events in multiple myeloma patients. J. Thorac. Dis. 10, S4296–S4305 (2018)
28.
C.T. Wallington-Beddoe, M. Sobieraj-Teague, B.J. Kuss, S.M. Pitson, Resistance to proteasome inhibitors and other targeted therapies in myeloma. Br. J. Haematol. 182, 11–28 (2018)CrossRef
29.
D.J.P.M. Stumpel, D. Schotte, P. Schneider, L. Seslija, R.X. de Menezes, V.E. Marquez, R. Pieters, M.L. den Boer, R.W. Stam, Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. Leukemia 25, 429–439 (2011)CrossRef
30.
M. Zauri, G. Berridge, M.-L. Thézénas, K.M. Pugh, R. Goldin, B.M. Kessler, S. Kriaucionis, CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature 524, 114–118 (2015)CrossRef
31.
R.Z. Mahfouz, A. Jankowska, Q. Ebrahem, X. Gu, V. Visconte, A. Tabarroki, P. Terse, J. Covey, K. Chan, Y. Ling, K.J. Engelke, M.A. Sekeres, R. Tiu, J. Maciejewski, T. Radivoyevitch, Y. Saunthararajah, Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin. Cancer Res. 19, 938–948 (2013)
32.
T. Neff, C.A. Blau, Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp. Hematol. 24, 1340–1346 (1996)PubMed
33.
H. Guo, N. Rao, Q. Xu, H. Guo, Origin of tight binding of a near-perfect transition-state analogue by cytidine deaminase: Implications for enzyme catalysis. J. Am. Chem. Soc. 127, 3191–3197 (2005)CrossRef
34.
P.L. Greenberg, E. Attar, J.M. Bennett, C.D. Bloomfield, C.M. De Castro, H.J. Deeg, J.M. Foran, K. Gaensler, G. Garcia-Manero, S.D. Gore, D. Head, R. Komrokji, L.J. Maness, M. Millenson, S.D. Nimer, M.R. O’Donnell, M.A. Schroeder, P.J. Shami, R.M. Stone, J.E. Thompson, P. Westervelt, National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J. Natl. Compr. Cancer Netw. JNCCN 9, 30–56 (2011)CrossRef
Metadaten
Titel
Zebularine-induced myeloma cell death is accompanied by decreased c-Myc expression
verfasst von
Patryk Krzeminski
Ramón García-Sanz
Norma C. Gutiérrez
Publikationsdatum
11.05.2020
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 4/2020
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-020-00516-6

Weitere Artikel der Ausgabe 4/2020

Cellular Oncology 4/2020 Zur Ausgabe

Review

Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance

Original paper

The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary

Original paper

Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma

Original paper

IL-17A and IL-17F orchestrate macrophages to promote lung cancer

Original paper

LINC00858 knockdown inhibits gastric cancer cell growth and induces apoptosis through reducing WNK2 promoter methylation

Original paper

Downregulation of beta-catenin in chemo-tolerant TNBC through changes in receptor and antagonist profiles of the WNT pathway: Clinical and prognostic implications

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Zielgerichtete Therapie Leitthema

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …